TriangleNCT02669914 · OUTCOME
Overall Response Rate Considering Both Intracranial and Extracranial Disease
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- COUNT_OF_PARTICIPANTS
- Unit
- Participants
- Interval / dispersion
- Not reported
- Time frame
- Completion of treatment (estimated to be 6 months)
What was measured
* Defined as the percentage of patients who achieve a complete response or partial response based on assessment of brain and systemic lesions * Intracranial disease * Complete response: Disappearance of all target lesions, non-target lesions, and normalization of tumor marker level. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. * Partial response: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters * Extracranial disease * Complete response: Disappearance of all target lesions, non-target lesions, and normalization of tumor marker level. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. * Partial response: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters
Analysis population: Two participants were not evaluable in Cohort A as the extracranial response per RECIST was not done. There were not any participants enrolled in Cohort B or Cohort C.
Groups in this outcome
Cohort A: Non-small Cell Lung Cancer w/o Corticosteroids
-MEDI4736 will be given to all patients \> 30 kg actual body weight intravenously at a fixed dose 750 mg every 2 weeks over the course of 60 minutes on an outpatient basis on Days 1 and 15 of each 28-day cycle. Patients \< 30 kg actual body weight will be dosed at 10 mg/kg every 2 weeks.
Cohort B: Epithelial Origin Solid Tumors w/o Corticosteroids
-MEDI4736 will be given to all patients \> 30 kg actual body weight intravenously at a fixed dose 750 mg every 2 weeks over the course of 60 minutes on an outpatient basis on Days 1 and 15 of each 28-day cycle. Patients \< 30 kg actual body weight will be dosed at 10 mg/kg every 2 weeks.
Cohort C: NSCLC or Non-NSCLC w/Corticosteroids
-MEDI4736 will be given to all patients \> 30 kg actual body weight intravenously at a fixed dose 750 mg every 2 weeks over the course of 60 minutes on an outpatient basis on Days 1 and 15 of each 28-day cycle. Patients \< 30 kg actual body weight will be dosed at 10 mg/kg every 2 weeks.
| Group | Source count |
|---|---|
| Cohort A: Non-small Cell Lung Cancer w/o Corticosteroids | 2 |
| Cohort B: Epithelial Origin Solid Tumors w/o Corticosteroids | 0 |
| Cohort C: NSCLC or Non-NSCLC w/Corticosteroids | 0 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Cohort A: Non-small Cell Lung Cancer w/o Corticosteroids | 0 | Not reported | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- value
- 0
- denoms
- counts
- group Id
- OG000
- value
- 2
- group Id
- OG001
- value
- 0
- group Id
- OG002
- value
- 0
- units
- Participants
- description
- * Defined as the percentage of patients who achieve a complete response or partial response based on assessment of brain and systemic lesions * Intracranial disease * Complete response: Disappearance of all target lesions, non-target lesions, and normalization of tumor marker level. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. * Partial response: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters * Extracranial disease * Complete response: Disappearance of all target lesions, non-target lesions, and normalization of tumor marker level. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. * Partial response: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters
- groups
- description
- -MEDI4736 will be given to all patients \> 30 kg actual body weight intravenously at a fixed dose 750 mg every 2 weeks over the course of 60 minutes on an outpatient basis on Days 1 and 15 of each 28-day cycle. Patients \< 30 kg actual body weight will be dosed at 10 mg/kg every 2 weeks.
- id
- OG000
- title
- Cohort A: Non-small Cell Lung Cancer w/o Corticosteroids
- description
- -MEDI4736 will be given to all patients \> 30 kg actual body weight intravenously at a fixed dose 750 mg every 2 weeks over the course of 60 minutes on an outpatient basis on Days 1 and 15 of each 28-day cycle. Patients \< 30 kg actual body weight will be dosed at 10 mg/kg every 2 weeks.
- id
- OG001
- title
- Cohort B: Epithelial Origin Solid Tumors w/o Corticosteroids
- description
- -MEDI4736 will be given to all patients \> 30 kg actual body weight intravenously at a fixed dose 750 mg every 2 weeks over the course of 60 minutes on an outpatient basis on Days 1 and 15 of each 28-day cycle. Patients \< 30 kg actual body weight will be dosed at 10 mg/kg every 2 weeks.
- id
- OG002
- title
- Cohort C: NSCLC or Non-NSCLC w/Corticosteroids
- param Type
- COUNT_OF_PARTICIPANTS
- population Description
- Two participants were not evaluable in Cohort A as the extracranial response per RECIST was not done. There were not any participants enrolled in Cohort B or Cohort C.
- reporting Status
- POSTED
- time Frame
- Completion of treatment (estimated to be 6 months)
- title
- Overall Response Rate Considering Both Intracranial and Extracranial Disease
- type
- SECONDARY
- unit Of Measure
- Participants
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice